drugset / Trial / NCT04007978
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
Phase 1
Unknown
50 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan Bio-Raid Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of anti-CD22 CAR-T cells in patients with relapsed or refractory B-cell Malignancies.
Timeline
- Start
- 2019-08-05
- Primary completion
- 2022-06-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD22 CAR T cells | Cell therapy | — | — |